STOCK TITAN
  1. Home
  2. Sec-filings
  3. AZN
  4. [6-K] ASTRAZENECA PLC Current Report (Foreign Issuer)

AstraZeneca adds 10,072 LSE shares from plans

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

AstraZeneca PLC (AZN) reported the admission of additional ordinary shares to trading on the London Stock Exchange Main Market. The company issued and admitted 10,072 ordinary shares of $0.25 each between 1 August 2026 and 31 August 2026 under existing employee share schemes and a prior block admission dated 29 January 2021.

Following this admission, AstraZeneca states that the total number of ordinary shares in issue is 1,551,043,461, which are fully fungible with the existing ordinary shares. No prospectus or supplementary prospectus was required for this admission.

Positive

  • None.

Negative

  • None.
Further securities issued and admitted 10,072 ordinary shares of $0.25 each Issued between 1 August 2026 and 31 August 2026 under employee share schemes
Total number of securities in issue following admission 1,551,043,461 ordinary shares Total shares in issue after admission of further securities
Ordinary share nominal value $0.25 per share Par value of each AstraZeneca ordinary share
Admission window 1 August 2026 to 31 August 2026 Period during which the newly admitted shares were issued
Block admission date 29 January 2021 Existing block admission under which the August 2026 shares were admitted
block admission regulatory
"admitted under a block admission dated 29 January 2021"
Public Offers and Admissions to Trading Regulations 2024 (POATRs) regulatory
"in accordance with The Public Offers and Admissions to Trading Regulations 2024"
employee share schemes financial
"Admission of shares under the Company's employee share schemes"
fungible financial
"Fully fungible with existing Ordinary Shares"
Fungible describes an asset that is interchangeable with another of the same kind because each unit holds the same value and function. For investors this matters because fungible assets are easier to trade, price, and store—think of cash or grains where one unit can replace another, unlike a unique artwork or a signed collectible which may be worth more or less depending on provenance. Fungibility affects liquidity, market efficiency, and how assets are settled or regulated.
regulated market regulatory
"Regulated market | London Stock Exchange - Main Market"
A regulated market is an organized trading venue overseen by government or independent authorities that enforces rules on who can list, what information must be published, and how trades are executed. Think of it like a store that must pass safety inspections and display clear labels: the oversight promotes honesty, regular reporting, and fair access, which helps investors compare options, find buyers and sellers, and reduces the risk of fraud or hidden problems.

FAQ

What did AstraZeneca PLC (AZN) announce in this September 2026 Form 6-K?
AstraZeneca PLC announced the admission of 10,072 additional ordinary shares of $0.25 each to trading on the London Stock Exchange Main Market, issued between 1 August 2026 and 31 August 2026 under the company’s employee share schemes.

How many AstraZeneca (AZN) shares are outstanding after this admission?
After this admission, AstraZeneca reports a total of 1,551,043,461 ordinary shares in issue. These shares are fully fungible with the company’s existing ordinary shares.

On which market are the new AstraZeneca (AZN) shares admitted to trading?
The additional AstraZeneca shares are admitted to trading on the Main Market of the London Stock Exchange, under an existing block admission dated 29 January 2021.

What is the source of the new AstraZeneca (AZN) shares admitted in August 2026?
The new shares arise from AstraZeneca’s employee share schemes, covering issuances from 1 August 2026 up to 31 August 2026 under an existing block admission of shares dated 29 January 2021.

Did AstraZeneca (AZN) use a prospectus for this share admission?
No. AstraZeneca states that both Prospectus: N/A and Supplementary: N/A applied to this admission of further securities to trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of September 2026 
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
1. Admission of Further Securities to Trading
 
 
 1 September 2026
 
 
Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
 
The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.
 
1
 
Details of the issuer
 
a)
 
Name
 
AstraZeneca PLC
 
b)
 
LEI
 
PY6ZZQWO2IZFZC3IOL08
 
2
 
Details of the transferable securities admitted to trading
 
a)
 
Name, type and identification code
 
Ordinary Shares of $0.25 each
 
ISIN: GB0009895292
 
b)
 
Regulated market
 
London Stock Exchange - Main Market
 
c)
 
Number of further securities issued and admitted
 
10,072
 
d)
 
Total number of securities in issue following admission
 
1,551,043,461
 
e)
 
Fungibility
 
Fully fungible with existing Ordinary Shares
 
3
 
Admission details
 
a)
 
Date of admission
 
Issued between 1 August 2026 to 31 August 2026 (admitted under a block admission dated 29 January 2021)
 
b)
 
Prospectus information
 
Prospectus: N/A
 
Supplementary: N/A
 
Company's webpage: https://www.astrazeneca.com
 
c)
 
Coverage of notification
 
Admission of shares under the Company's employee share schemes from 1 August 2026 up to 31 August 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021. 
 
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
 
Matthew Bowden
Company Secretary
AstraZeneca PLC
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
Date: 01 September 2026
 
 
By: /s/ Matthew Bowden
 
Name: Matthew Bowden
 
Title: Company Secretary

Source: View Original Filing on SEC EDGAR